Collaboration at Its Core: Launching Spain’s First Fully Integrated Spatial Omics Platform
IRB Barcelona has unveiled Spain’s first fully integrated spatial omics platform, uniting spatial transcriptomics, proteomics, histopathology, advanced microscopy and bioinformatics under one workflow. The facility draws on five core units to deliver an end‑to‑end pipeline from sample preparation through computational interpretation, and is open to academic, hospital and industry researchers. By offering high‑resolution, spatially resolved molecular maps, the platform aims to accelerate discovery in cancer, neurodegeneration, cardiovascular and immune disorders. The launch reinforces IRB’s legacy as a national and European reference centre for cutting‑edge biomedical technologies.
Voyageur Pharmaceuticals Secures Iodine Collaboration with Bayer
Voyageur Pharmaceuticals announced a milestone‑based collaboration with Bayer that could provide up to US$2.35 million to fund an iodine extraction feasibility study in Oklahoma. The agreement releases $350,000 at signing, $1 million when the study starts, and another $1 million upon its completion,...
Module 2, Section 1: Target Selection Strategy
The module outlines a five‑dimensional framework for target selection, linking biological relevance, drugability, disease impact, competitive landscape, and development risk. It contrasts first‑in‑class and best‑in‑class strategies, highlighting how pioneering mechanisms can command premium market positions. The content identifies oncology as...
OMG as a Marker of Resiliency to Neurodegenerative Processes
Researchers identified oligodendrocyte myelin glycoprotein (OMG) in blood as a marker inversely associated with cortical amyloid‑β deposition and neurodegeneration. Large‑scale plasma proteomics across more than a dozen cohorts showed lower OMG levels in individuals with Alzheimer’s disease, other dementias, and...
How FDA's Action Against Non-FDA-Approved GLP-1 Products Affects the Competitive Landscape
Jay Bregman, CEO of Andel, says the FDA’s pending crackdown on non‑FDA‑approved GLP‑1 compounds is long overdue and will target the burgeoning market of compounded semaglutide. He estimates roughly 1.5 million patients currently rely on these unapproved products, a figure he...
Pharma Pulse: MRNA Legal Wars and the Community Pharmacy Shield
BioNTech has filed a Delaware patent‑infringement lawsuit against Moderna, accusing the latter’s next‑generation COVID vaccine mNEXSPIKE of using BioNTech’s streamlined mRNA design. The disputed shot is projected to generate about 55 % of Moderna’s COVID revenue this season, making the case...
The Government’s Warning Shot? FDA and HHS Turn Up the Pressure on Compounding
The FDA, backed by HHS, issued a stark warning to compounding pharmacies that market GLP‑1 products such as semaglutide, after Hims & Hers promoted a compounded Wegovy copy. A press release announced intent to restrict non‑approved GLP‑1 APIs and referred...
GLP-1 Drugs Fail to Slow Cognitive Decline in Alzheimer’s Disease
Recent randomized trials testing GLP‑1 receptor agonists such as semaglutide and liraglutide in Alzheimer’s disease patients found no measurable slowing of cognitive decline. Earlier post‑hoc and observational analyses had suggested roughly a 50 % reduction in dementia incidence, raising hopes of...
Eli Lilly Invests $3.5B in Pennsylvania to Scale Next‑Gen Obesity Drug Manufacturing
Eli Lilly announced a $3.5 billion investment to build a new injectable‑medicine plant in Lehigh Valley, Pennsylvania. The facility, slated to break ground in 2026 and run by 2031, will focus on next‑generation obesity and metabolic drugs such as the triple‑agonist retatrutide....
Novartis Breaks Ground on $23B Biomedical Research Hub in San Diego
Novartis began construction of a new biomedical research hub in San Diego. The 466,000‑sq‑ft center, part of a $23 billion US R&D and manufacturing program, will house about 1,000 researchers and target neuroscience, oncology, global health, and age‑related diseases. Scheduled to...
Topical Adquey (Difamilast) Wins FDA Approval for Atopic Dermatitis
The U.S. Food and Drug Administration has granted approval to Adquey, a 1% difamilast topical ointment, for the treatment of mild-to-moderate atopic dermatitis in patients two years and older. Developed by Otsuka and licensed to Acrotech Biopharma, the product is...
Supreme Court Rejection of Trump Tariffs Has Nuanced Implications for Pharma Importers
The Supreme Court struck down the broad tariffs imposed under the International Emergency Economic Powers Act, but left Section 232 duties untouched. Because most pharma tariffs were issued under Section 232, the ruling does not eliminate the targeted tariffs on drug imports....
AI Tool Sets New Standard in Diagnosing Rare Diseases
A new multi‑agent system called DeepRare, built on the DeepSeek‑V3 large language model and over 40 specialized tools, outperformed 15 competing AI models and human physicians in diagnosing rare diseases. Across 6,401 cases covering 2,919 rare conditions, it achieved a...
From Junk Science (Largely Non-Political) to Junk Medical Treatments (Mostly Associated with the Far-Right): A Financial Connection
Paul Krugman highlights a growing financial link between the multi‑billion‑dollar wellness industry and right‑wing extremist movements. He notes that U.S. spending on wellness reaches roughly $500 billion annually, with nutritional supplements alone accounting for about $70 billion, while regulators like the FDA...
The Pulse of Pharma Change in 2026
In a February 20, 2026 Pharm Exec Podcast, ZS CEO Pratap Khedkar, PhD, outlined three converging trends reshaping pharma: heightened AI integration, evolving ecosystem partnerships, and sweeping US‑driven policy reforms. Drawing on his nine‑year tenure leading ZS’s global pharmaceuticals practice and its advanced data‑science...
Pharma Pulse: J&J’s $1B Cell Therapy Hub and Hims & Hers’ Global Expansion
Johnson & Johnson announced a $1 billion investment to build a next‑generation cell‑therapy manufacturing facility in Montgomery County, Pennsylvania, slated to support 500 skilled jobs. The hub is a key element of J&J’s $55 billion U.S. manufacturing, R&D, and technology strategy. Meanwhile,...
Rare Disease Month Developments – Part 3: The Ugly (Just Kidding) – See You at Rare Disease Week
Rare Disease Week convenes on Capitol Hill, bringing patients, advocates, regulators, and industry together to shape policy for rare disease therapies. Hyman, Phelps & McNamara will be prominently represented, highlighted by Frank Sasinowski receiving the EveryLife Foundation’s Abbey Lifetime Achievement...
Pharmaceutical Executive Daily: FDA Plans to Remove Two Study Requirement for New Drug Approvals
The FDA announced it will drop the historic requirement for two adequate and well‑controlled studies in certain new‑drug approval pathways, a move that could accelerate timelines and lower development costs. The change is especially relevant for therapies targeting unmet medical...
ACIP February Meeting Cancelled: Report
The Advisory Committee on Immunization Practices (ACIP) cancelled its scheduled February 25‑27, 2026 meeting, and no new date has been announced. The cancellation occurs amid a wave of senior HHS leadership changes, including the departure of Deputy Secretary Jim O’Neill and General...
Eli Lilly Announces Positive Results for Treating Crohn’s Disease with Omvoh
Eli Lilly reported that its biologic Omvoh (mirikizumab) sustained steroid‑free remission for three years in Crohn’s disease patients in the Phase 3 VIVID‑2 open‑label extension study. More than 90% of participants remained in remission, with 80% experiencing relief from bowel urgency. The...
From Launch to Loss of Exclusivity- Reducing Access and Affordability Barriers Across the Brand Lifecycle
CoverMyMeds outlines how access and affordability challenges evolve across a biopharma brand’s lifecycle, from launch through loss of exclusivity, and offers actionable, data‑driven strategies to mitigate them. The firm emphasizes real‑time analytics, provider‑focused tools, and tailored patient assistance to reduce...
A Circulating Inflammation Suppressor Decreases Mortality
Researchers used Mendelian randomization to demonstrate that the inflammatory cytokine IL6 directly increases all‑cause mortality, while its soluble receptor IL6R has the opposite effect. Elevated circulating IL6R was linked to lower risk of lung cancer, diabetes, stroke and coronary artery...
CMS Broadens Drug Price Negotiations to Part B Therapies
The Centers for Medicare & Medicaid Services announced a third round of drug price negotiations that for the first time includes Part B physician‑administered therapies. By extending the Inflation Reduction Act’s pricing provisions to infused medicines, the move pulls doctors into...
Pharma Pulse: FDA’s Moderna Reversal and Eli Lilly’s $100 Million IL-6 Bet
The FDA has reversed its earlier refusal-to-file and will review Moderna’s seasonal mRNA influenza vaccine, with a decision slated for August 5, 2026. Moderna now seeks full approval for adults aged 50‑64 and accelerated approval for those 65 and older. Meanwhile, Eli Lilly...
Antioxidant Nanoparticles May Protect Male Fertility During Chemotherapy
A preclinical study published in Reproductive and Developmental Medicine found that combining melatonin with zinc oxide nanoparticles mitigates cyclophosphamide‑induced reproductive toxicity in male rats. The antioxidant duo restored testosterone and luteinizing hormone levels, lowered oxidative stress markers, and preserved spermatogenic...
UV Red Flag: Color-Changing ‘Living’ Material Warns of Harmful Radiation
Researchers at the Technical University of Munich have created a bio‑hybrid coating that visibly signals UV‑A exposure by turning from green to red. The sensor embeds dry Escherichia coli cells loaded with the photoconvertible protein mEosFP, which undergoes an irreversible...
Genentech’s Fenebrutinib Yields Positive Results in Phase III MS Trial
Genentech’s oral BTK inhibitor fenebrutinib met its primary endpoint in the Phase III FENtrepid trial for primary progressive multiple sclerosis, showing non‑inferiority to Ocrevus and a 12% risk reduction in confirmed disability progression. The drug also delivered a 26% lower risk...
Anti-Aging Gene Therapy in Alzheimer’s and ALS with Klotho Neurosciences’ Dr. Joseph Sinkule — Episode 243
The Xtalks Life Science Podcast featured Joseph Sinkule, CEO of Klotho Neurosciences, discussing the company’s secreted α‑Klotho gene therapy platform aimed at age‑related neurodegenerative diseases such as Alzheimer’s, ALS and Parkinson’s. Klotho leverages a patented anti‑aging gene to develop cell‑ and...
Global Conference to Tackle Longevity Clinical Translation
The National University of Singapore Academy for Healthy Longevity is hosting the Geromedicine Conference on February 26-27, 2026, bringing together geroscience researchers, clinicians, and industry leaders. The event emphasizes clinical translation of molecules such as NAD+ precursors, urolithin A, and ergothioneine,...
How Does Cholera Colonize the Gut? Unmasking Virulence Activation with Cryo-EM
Cryogenic electron microscopy enabled researchers to solve five structures of Vibrio cholerae transcription activation complexes, revealing how the bacterium initiates virulence in the human gut. The study shows ToxR and TcpP transcription factors bind the RNA polymerase α‑C‑terminal domain via...
Patent Cliff Pressures to Drive Big Pharma M&A
The looming patent cliff, projected to strip up to $300 billion in annual drug sales by 2032, is keeping large pharma firms focused on strategic acquisitions rather than triggering a sudden surge in deal volume. Dan Chancellor of Norstella notes that...
Global Genomics: Representative Research Is Key to Unlocking the Full Potential of Precision Medicine
Professor Segun Fatumo highlights the stark under‑representation of African genomes in global research, where over 86% of GWAS participants are of European ancestry despite Africa housing the greatest genetic diversity. He explains how this gap limits the accuracy of polygenic...
The Biotech Bi-Weekly: A 48-Channel SPR Platform, Robust RNA-Seq Libraries and Microgravitational Discoveries
Carterra unveiled Vega, the industry’s first 48‑channel high‑throughput SPR platform, delivering roughly 12‑fold higher screening capacity for small‑ and large‑molecule drug candidates. Covaris introduced the truCOVER® Total RNA Library Prep Kit, enabling robust RNA‑seq libraries from as little as 10 ng...
Free Access to Single-Cell Long-Read mRNA Sequencing Tech with New Grant
ArgenTag, now a PacBio Compatible Partner, has launched a grant that provides free access to its Single‑Cell RNA Library Kit for Long‑Read Sequencing. The kit uses a gravity‑based microfluidic chip to isolate individual cells, capture full‑length mRNA, and prepare barcoded...
Rare Disease Month Developments, Part 1 – The Good: RPD PRV Program Renewed, FDA Rare Disease Hub’s 2026 Strategic Agenda...
Congress renewed the Rare Pediatric Disease Priority Review Voucher (RPD PRV) program, extending it to September 30 2029 and eliminating the dual sunset dates. The FDA released its Rare Disease Innovation Hub’s 2026 Strategic Agenda, allocating $1 million in funding and outlining plans...
Silencing Growth Hormone Has Strong Effects in Mouse Brains
Researchers engineered mice lacking growth hormone receptors specifically in adipose tissue (Ad‑GHRKO) and observed striking brain benefits in aged males. Compared with control mice, the Ad‑GHRKO group showed increased neuronal activity, reduced neuroinflammation, lower tau phosphorylation, and fewer senescence markers....
Who Qualifies for the New FDA PreCheck Pilot Program?
The FDA has opened submissions for its PreCheck Pilot Program, targeting new U.S. drug‑manufacturing facilities that will begin construction by the March 1 2026 deadline. Eligible sites must be stand‑alone plants, located in the United States or its territories, and commit to...
Longevity Innovation Forum in San Diego
Longevity Global is launching the inaugural Longevity Innovation Forum in San Diego on March 11‑12, 2026, gathering leading scientists, clinicians, biotech founders and investors to accelerate healthy‑aging research. The two‑day summit features high‑profile speakers such as Mike Snyder, Eric Verdin,...
Cellular Reprogramming Rescues Memory-Encoding Neurons
Scientists at EPFL applied a three‑factor (OSK) partial reprogramming cocktail to memory‑encoding engram neurons in 9‑10‑month‑old mice and Alzheimer’s‑model strains. Using a dual‑AAV system gated by doxycycline, OSK expression was limited to neurons active during a learning event, preserving cell...
Creating CAR-T Cells Using Current Alzheimer’s Antibodies
Researchers engineered CD4+ T cells with chimeric antigen receptors (CARs) derived from FDA‑approved Alzheimer’s antibodies aducanumab and lecanemab. The lecanemab‑based CAR (Lec28z) selectively bound fibrillar amyloid‑beta and reduced plaque burden in mouse brains, especially when delivered via transient mRNA transfection....
Can a Citizen Petition Denial Turn a Warning Letter Into Final Agency Action? The Curious Case of Hybrid Pharma
The Southern District of Florida held that a denial of a citizen petition transforms the underlying FDA warning letters into final agency action, allowing judicial review. Hybrid Pharma sued after the FDA refused to rescind two warning letters and the...
Young Microbes Rejuvenate Intestinal Function in Mice
Researchers performed heterochronic fecal microbiota transplants, moving gut microbes from young to aged mice, which reactivated canonical Wnt signaling and enhanced intestinal stem cell regeneration. Aged mice receiving young microbiota showed increased expression of Wnt3, Ascl2, Lgr5 and improved epithelial...
ACI’s 22nd Annual Paragraph IV Disputes: Elevate Your 2026 Hatch-Waxman Strategy
The American Conference Institute will host its 22nd Annual Paragraph IV Disputes Conference on April 21‑22, 2026 in New York’s Times Center. The two‑day forum gathers brand‑name and generic drug stakeholders to discuss Hatch‑Waxman litigation strategies, recent case law, and evolving PTAB practices. Featured...
Sixth Circuit Affirms Steep Sentence in FDC Act Counterfeiting Case
The Sixth Circuit Court of Appeals affirmed a 90‑month prison term for Omar Wala, who pleaded guilty to conspiring to manufacture and distribute counterfeit generic alprazolam pills on the dark web. The court upheld the district court’s fraud loss calculation,...